Incyte Investor Relations Material
Latest events
Investor Update
Incyte
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Incyte Corporation
Access all reports
Incyte is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company develops next generation medicines across its three core therapeutic platforms: cancer immunology, epigenetics and targeting microRNAs. The company's epigenetics platform is focused on technologies that can reprogram adult cells to their embryonic state to make them fertile ground for drug discovery.
Key slides for Incyte Corporation
Q1 2025
Incyte Corporation
Investor Update
Incyte Corporation
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
INCY
Country
🇺🇸 United States